Search
Citations & References (26)
Invitrogen™
TNF alpha Human ProcartaPlex™ Simplex Kit
The Human TNF alpha Simplex ProcartaPlex Kit measures TNF alpha protein and is designed to be combinable with other SimplexRead more
| Catalog Number | Quantity |
|---|---|
| EPX01A-10223-901 | 96 Tests |
Catalog number EPX01A-10223-901
Price (CNY)
-
Quantity:
96 Tests
The Human TNF alpha Simplex ProcartaPlex Kit measures TNF alpha protein and is designed to be combinable with other Simplex kits so that you can create your own multiplex panel that utilizes Luminex xMAP technology for protein detection/quantitation. When combining multiple Simplex kits (i.e., when you are not using a pre-configured Multiplex Panel), only one buffer kit (sold separately) is needed for each assay plate regardless of plex size.
About ProcartaPlex Assays for the Luminex Platform
ProcartaPlex immunoassays are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously using a Luminex instrument. ProcartaPlex multiplex assays require as little as 25 μL of plasma or serum, or 50 μL of cell culture supernatant, and just four hours to obtain analyzed results.
• More results per sample—measure multiple protein targets simultaneously in a single 25–50 μL sample
•Well-established Luminex technology—highly referenced multiplexing platform for protein detection and quantitation
ProcartaPlex assays utilize Luminex xMAP (multianalyte profiling) technology for the simultaneous detection and quantitation of up to 80 protein targets in a single 25–50 μL sample from plasma, serum, cell culture supernatants, and other bodily fluids.
The Luminex beads in the ProcartaPlex assay are internally dyed with precise proportions of red and infrared fluorophores to create spectrally unique signatures that can be identified by the Luminex xMAP detection systems (e.g. Luminex 200, FLEXMAP 3D, and MAGPIX). Similar to a sandwich ELISA, the ProcartaPlex assay uses matched antibody pairs to identify the protein of interest. In a multiplexed assay, each spectrally unique bead is labeled with antibodies specific for a single target protein, and bound proteins are identified with biotinylated antibodies and streptavidin–R-phycoerythrin (RPE). The conjugation of protein-specific antibodies to a distinct bead allows for analysis of multiple targets in a single well.
The most significant difference between a ProcartaPlex assay and ELISA is that the capture antibody in the ProcartaPlex assay is conjugated to a bead and not adsorbed to the microplate well, so the ProcartaPlex assay reagents are free-floating in the solution. For detection, the Luminex 200 instrument, for example, contains two lasers, one to distinguish the spectral signature of each bead and the second to quantify the amount of RPE fluorescence, which is proportional to the amount of protein present in the sample. ProcartaPlex multiplex assays can profile more target proteins using significantly less sample in the same time that it takes to perform a traditional sandwich ELISA.
ProcartaPlex multiplex panels are available in multiple formats across six species (human, mouse, rat, nonhuman primate, porcine, and canine). Visit thermofisher.cn/procartaplex for more information, including a comprehensive list of individual protein targets.
About ProcartaPlex Assays for the Luminex Platform
ProcartaPlex immunoassays are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously using a Luminex instrument. ProcartaPlex multiplex assays require as little as 25 μL of plasma or serum, or 50 μL of cell culture supernatant, and just four hours to obtain analyzed results.
• More results per sample—measure multiple protein targets simultaneously in a single 25–50 μL sample
•Well-established Luminex technology—highly referenced multiplexing platform for protein detection and quantitation
ProcartaPlex assays utilize Luminex xMAP (multianalyte profiling) technology for the simultaneous detection and quantitation of up to 80 protein targets in a single 25–50 μL sample from plasma, serum, cell culture supernatants, and other bodily fluids.
The Luminex beads in the ProcartaPlex assay are internally dyed with precise proportions of red and infrared fluorophores to create spectrally unique signatures that can be identified by the Luminex xMAP detection systems (e.g. Luminex 200, FLEXMAP 3D, and MAGPIX). Similar to a sandwich ELISA, the ProcartaPlex assay uses matched antibody pairs to identify the protein of interest. In a multiplexed assay, each spectrally unique bead is labeled with antibodies specific for a single target protein, and bound proteins are identified with biotinylated antibodies and streptavidin–R-phycoerythrin (RPE). The conjugation of protein-specific antibodies to a distinct bead allows for analysis of multiple targets in a single well.
The most significant difference between a ProcartaPlex assay and ELISA is that the capture antibody in the ProcartaPlex assay is conjugated to a bead and not adsorbed to the microplate well, so the ProcartaPlex assay reagents are free-floating in the solution. For detection, the Luminex 200 instrument, for example, contains two lasers, one to distinguish the spectral signature of each bead and the second to quantify the amount of RPE fluorescence, which is proportional to the amount of protein present in the sample. ProcartaPlex multiplex assays can profile more target proteins using significantly less sample in the same time that it takes to perform a traditional sandwich ELISA.
ProcartaPlex multiplex panels are available in multiple formats across six species (human, mouse, rat, nonhuman primate, porcine, and canine). Visit thermofisher.cn/procartaplex for more information, including a comprehensive list of individual protein targets.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Assay RangeAs determined for Lot 1: 8.54 - 35,000 pg/mL
Assay SensitivityAs determined for Lot 1: 0.4 pg/mL
Bead TypeTNF alpha [45]
For Use With (Equipment)Luminex™ Instruments
FormatSimplex Kit
Genetumor necrosis factor
Gene AliasDIF-alpha, TNFA, TNFSF2, TNLG1F, TNF
Gene ID (Entrez)7124
Gene SymbolTNF
Product LineProcartaPlex
ProteinTumor necrosis factor
Protein SubtypeCachectin, TNF-alpha
Sample TypeSerum, Plasma, Cell Culture Supernatants
Sample VolumeSerum, Plasma: 25 μL; CCS: 50 μL
Shipping ConditionWet Ice
UniProt IDP01375
CombinabilityCombinable
Product TypeSimplex Kit
Quantity96 Tests
Research AreaImmunology, Oncology, Neurobiology, Toxicology, Cytokines
SpeciesHuman
Unit SizeEach
Contents & Storage
• 1 vial Capture Beads (50X)
• 1 vial biotinylated Detection Antibody (50X)
• 2 vials Human Standard Mix A (lyophilized)
Store at 2°C to 8°C.
Frequently asked questions (FAQs)
What is the size of the Luminex beads you currently use?
I am interested in performing Luminex assays using BioSource kits, and I have a Luminex xMAP system. Besides the kits and system, what other reagents and equipment will I need?
Do the Luminex beads require special care in handling?
Why would the Luminex acquisition software display "Sample Empty" messages during analysis?
What are the Luminex beads made of?
Citations & References (26)
Citations & References
Abstract
Endotracheal tube-induced sore throat pain and inflammation is coupled to the release of mitochondrial DNA.
Journal:
PubMed ID:28929859
In the absence of infection, the pathophysiology of endotracheal tube-induced sore throat pain is unclear. Activated neutrophils release elastase, reactive oxygen species, and inflammatory cytokines known to contribute to neuropathic pain. Sterile tissue injury can cause the release of damage-associated molecular patterns such as mitochondrial DNA that promote neutrophil activation.
Inflammatory Effects of the Plant Protection Product Stifenia (FEN560) on Vertebrates.
Journal:Front Public Health
PubMed ID:28484691
'Plant defense stimulators (PDSs) rely on the activation of plant innate immunity in order to protect crops against various pests. These molecules are thought to be a safer alternative to classical plant protection products. Given that innate immune systems share common features in plants and vertebrates, PDS can potentially cross-react
Immunomodulating protein aggregates in soy and whey hydrolysates and their resistance to digestion in an in vitro infant gastrointestinal model: new insights in the mechanism of immunomodulatory hydrolysates.
Journal:Food Funct
PubMed ID:29271442
'Hydrolysates, which are used in hypoallergenic infant formulas, have been found to possess immune modulating effects. For an optimal utilization of hydrolysates, the working mechanisms and responsible proteins underlying the effects should be elucidated. In this study, the immunomodulating activity of whey and soy hydrolysates was studied by quantifying TLR
Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients.
Journal:J Cachexia Sarcopenia Muscle
PubMed ID:29316343
'Cancer-associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose. While increases in circulating levels of a number of inflammatory cytokines have been associated with cancer cachexia, these associations were generally made in patients with advanced
Impaired efferocytosis by monocytes in multiple myeloma.
Journal:Oncol Lett
PubMed ID:29928429
'Efficient clearance of apoptotic cells by efferocytosis is important for tissue homeostasis. Impaired efferocytosis leads to the accumulation of cell debris, which is regarded as a trigger in chronic inflammation and autoimmune diseases. Patients with hematological neoplastic disorders such as multiple myeloma (MM) exhibit high blood levels of apoptotic microparticles.